Literature DB >> 23259986

Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia.

Emilie Laprevotte1, Loïc Ysebaert, Christian Klein, Wilfried Valleron, Amandine Blanc, Emilie Gross, Guy Laurent, Jean-Jacques Fournié, Anne Quillet-Mary.   

Abstract

Rituximab (RTX, anti-CD20 antibody) combined with chemotherapy is currently standard treatment for chronic lymphocytic leukemia (CLL). Serum level of IL-8 is a prognostic factor for CLL that correlates with disease stage. We investigated whether endogenous IL-8 affects RTX or Obinutuzumab (GA101) B-leukemic depletion mediated by natural killers (NK). Using whole peripheral blood lymphocytes from untreated CLL patients, RTX, but most significantly GA101, were effective in B-cell depletion and NK activation. IL-8 inhibition completely inhibited B-cell depletion by RTX and reduced GA101-induced B-cell depletion. Altogether results underline IL-8 as an endogenous NK co-activator and confirm GA101 therapeutic potential for CLL treatment.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23259986     DOI： 10.1016/j.leukres.2012.11.015

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  8 in total

1.  Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.

Authors:  Ciara L Freeman; Franck Morschhauser; Laurie Sehn; Mark Dixon; Richard Houghton; Thierry Lamy; Günter Fingerle-Rowson; Elisabeth Wassner-Fritsch; John G Gribben; Michael Hallek; Gilles Salles; Guillaume Cartron
Journal:  Blood       Date:  2015-10-07       Impact factor: 22.113

2.  Flow Cytometry-based Assay for the Monitoring of NK Cell Functions.

Authors:  Sara Tognarelli; Benedikt Jacobs; Nina Staiger; Evelyn Ullrich
Journal:  J Vis Exp       Date:  2016-10-30       Impact factor: 1.355

3.  Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity.

Authors:  Ricardo García-Muñoz; Ascensión López-Díaz-de-Cerio; Jesus Feliu; Angel Panizo; Pilar Giraldo; Mercedes Rodríguez-Calvillo; Carlos Grande; Esther Pena; Mayte Olave; Carlos Panizo; Susana Inogés
Journal:  Immunol Res       Date:  2016-04       Impact factor: 2.829

4.  Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment.

Authors:  S Betrian; L Ysebaert; K H Heider; J P Delord; J J Fournié; A Quillet-Mary
Journal:  Blood Cancer J       Date:  2016-11-11       Impact factor: 11.037

Review 5.  A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.

Authors:  Kensei Tobinai; Christian Klein; Naoko Oya; Günter Fingerle-Rowson
Journal:  Adv Ther       Date:  2016-12-21       Impact factor: 3.845

6.  Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse.

Authors:  Sarah Cadot; Carine Valle; Marie Tosolini; Frederic Pont; Laetitia Largeaud; Camille Laurent; Jean Jacques Fournie; Loic Ysebaert; Anne Quillet-Mary
Journal:  Biomark Res       Date:  2020-12-09

7.  Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers.

Authors:  L Ysebaert; E Laprévotte; C Klein; A Quillet-Mary
Journal:  Blood Cancer J       Date:  2015-11-13       Impact factor: 11.037

8.  Monocyte-Derived Signals Activate Human Natural Killer Cells in Response to Leishmania Parasites.

Authors:  Helena Messlinger; Heidi Sebald; Lukas Heger; Diana Dudziak; Christian Bogdan; Ulrike Schleicher
Journal:  Front Immunol       Date:  2018-01-24       Impact factor: 7.561
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.